2011
DOI: 10.1002/mds.23670
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Although alpha-synuclein is the main constituent of Lewy bodies, cerebrospinal fluid determination on its own does not seem fundamental for the diagnosis of synucleinopathies. We evaluated whether the combination of classical biomarkers, Aβ(1-42) , total tau, phosphorylated tau, and α-synuclein can improve discrimination of Parkinson's disease, dementia with Lewy bodies, Alzheimer's disease, and frontotemporal dementia. Aβ(1-42) , total tau, phosphorylated tau, and α-synuclein were measured in a series of pati… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

23
139
4

Year Published

2011
2011
2021
2021

Publication Types

Select...
6
1

Relationship

2
5

Authors

Journals

citations
Cited by 155 publications
(166 citation statements)
references
References 40 publications
23
139
4
Order By: Relevance
“…However, although one of those studies found no change in CSF ␣-synuclein in PD patients (20), the other demonstrated reduced ␣-synuclein in PD CSF when samples were corrected for erythrocyte contamination. Moreover, reduced CSF ␣-synuclein in PD patients has also been reported in studies that interpolated slightly higher (2-4-fold) (15,16) or dramatically higher (Ͼ30-fold) (18,21) absolute concentrations of CSF ␣-synuclein in comparison to our study. More work is necessary to understand the nature of changes of CSF ␣-synuclein abundance and species in PD progression (e.g.…”
Section: Volume 287 • Number 40 • September 28 2012supporting
confidence: 84%
See 2 more Smart Citations
“…However, although one of those studies found no change in CSF ␣-synuclein in PD patients (20), the other demonstrated reduced ␣-synuclein in PD CSF when samples were corrected for erythrocyte contamination. Moreover, reduced CSF ␣-synuclein in PD patients has also been reported in studies that interpolated slightly higher (2-4-fold) (15,16) or dramatically higher (Ͼ30-fold) (18,21) absolute concentrations of CSF ␣-synuclein in comparison to our study. More work is necessary to understand the nature of changes of CSF ␣-synuclein abundance and species in PD progression (e.g.…”
Section: Volume 287 • Number 40 • September 28 2012supporting
confidence: 84%
“…Earlier studies utilizing capture-based immunoassays demonstrated reduced ␣-synuclein in the CSF of PD patients, relative to those of control cohorts (15)(16)(17)(18)21). We present here similar findings in a small cohort of PD and control patients, thereby potentially increasing the utility of CSF ␣-synuclein content as a PD biomarker.…”
Section: Volume 287 • Number 40 • September 28 2012supporting
confidence: 84%
See 1 more Smart Citation
“…Some studies have shown some negative correlation of -syn with age (Mollenhauer et al, 2008;Tokuda et al, 2006;Ohrfelt et al, 2009;Noguchi-Shinohara et al, 2009;Parnetti et al, 2011), whereas one study (Hong et al, 2010) reported an opposite trend. In some studies reduced levels of -syn in CSF from PD and DLB have been detected compared to controls or AD (Tokuda et al, 2006;Mollenhauer et al, 2008;Tokuda et al, 2010;Kasuga et al, 2010;Hong et al, 2010;Parnetti et al, 2011). Conversely, in other studies no significant difference between groups was observed (Öhrfelt et al, 2009;NoguchiShinohara et al, 2009;Spies et al, 2009).…”
Section: Alpha-synuclein As Disease-state Markermentioning
confidence: 96%
“…Whether -syn is a marker of trait or a marker of progression is under investigation. According to the knowledge so far collected no clear-cut correlation with disease duration or disease severity (Hong et al, 2010;Parnetti et al, 2011) has been highlighted, suggesting that decrease of CSF -syn is a marker of trait in synucleinopathies.…”
Section: Alpha-synuclein As Disease-state Markermentioning
confidence: 99%